Inhibikase Therapeutics Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 17 | Q4 17 | Q1 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | 81.9 | 32.9 | 11.5 | 14.6 | 12.2 | 21.7 | 49.0 | 371.4 | 68.8 | 90.0 | 60.4 | 19.5 | 30.9 | 71.2 | 113.6 | 11,547,341.0 | 2,046.9 | 7,497.2 | 6,851.6 | 5,483.8 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 5.8 | 7.5 | 0.7 | 1.1 | 1.0 | 1.1 | 0.6 | 0.9 | 0.6 | 0.7 | 1.0 | 0.5 | 0.7 | 2.1 | 1.8 | – | 0.6 | 2.3 | 2.2 | 2.0 | 1.1 | 1.7 | 2.3 | |
| – | – | – | – | – | – | – | – | – | – | – | 62.4 | 28.3 | -4.0 | 1.0 | -0.9 | – | – | 280.1 | 30.4 | 71.1 | 54.7 | -18.8 | -2.3 | 61.4 | 79.0 | 10,850,793.0 | -98.9 | 4,704.8 | 3,894.1 | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -2.0% | -8.0% | -26.4% | -23.3% | -37.8% | -37.8% | -77.0% | -79.0% | -137.9% | -107.0% | -104.2% | -240.8% | -225.1% | -114.7% | -182.1% | -149.3% | -35.6% | -9.8% | -11.1% | -17.8% | -14.3% | -12.4% | -12.3% | |
| Margins | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | -127.4% | -59.5% | -25.0% | -21.7% | -28.0% | -65.8% | -73.3% | -150.7% | -266.4% | -586.7% | -3,175.3% | -15,091.6% | -3,176.3% | -1,383.6% | 45.1% | 54.2% | 31.9% | 8.7% | 67.0% | -2,627,200.0% | -100.0% | -123.2% | -190.1% | -255.3% | – | – | – | |
| – | – | – | – | – | – | -293.4% | -507.5% | -561.5% | -301.8% | -265.5% | -403.5% | -267.3% | -239.0% | -334.2% | -476.2% | -964.7% | -4,907.0% | -30,468.6% | -9,889.4% | -9,020.2% | -6,342.0% | -5,214.7% | -7,712.0% | -10,285.3% | -23,885.1% | -2,006,393,700.0% | -108,811.3% | -146,170.0% | -168,175.6% | -194,593.0% | – | – | – | |
| – | – | – | – | – | – | -294.4% | -509.7% | -565.0% | -305.4% | -269.4% | -407.7% | -269.1% | -240.1% | -335.0% | -476.9% | -965.2% | -4,907.1% | -30,438.9% | -9,787.8% | -8,810.3% | -6,069.9% | -4,953.4% | -7,304.8% | -9,797.3% | -23,102.2% | -1,956,524,900.0% | -104,741.9% | -139,107.0% | -157,969.5% | -181,385.1% | – | – | – | |
| – | – | – | – | – | – | – | -30.1% | -38.0% | -31.2% | -24.0% | -162.8% | -262.5% | -303.9% | -341.0% | -461.1% | -821.9% | -3,772.8% | -29,334.2% | -9,488.7% | -9,629.3% | -6,293.0% | -4,691.6% | -6,947.9% | -8,161.1% | -20,697.4% | -1,724,492,300.0% | -72,878.4% | -73,778.6% | -75,757.2% | -97,495.9% | – | – | – | |
| Returns | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | -29.1% | -61.4% | -15.2% | -25.4% | -38.5% | -49.4% | -63.7% | -74.9% | -85.3% | -70.2% | -97.2% | -126.6% | -173.3% | -283.3% | -360.7% | – | -29.0% | -42.6% | -51.8% | -65.4% | -27.9% | -30.4% | -39.5% | |
| – | – | – | – | – | – | – | -14,960.5% | -12,040.5% | -712.3% | -141.4% | -19.3% | -41.6% | -14.5% | -23.9% | -34.8% | -43.7% | -55.3% | -65.8% | -72.0% | -63.1% | -84.7% | -106.4% | -131.2% | -173.5% | -208.3% | -447.0% | -27.9% | -38.8% | -46.7% | -59.9% | -26.6% | -29.4% | -37.1% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||
| – | 0.4 | 0.4 | -0.1 | – | – | – | 0.4 | 0.6 | 0.7 | 0.7 | -14 | -8.4 | -46 | -45 | -41 | – | – | -5.6 | -7.0 | -3.8 | -1.8 | -15 | -8.6 | -1.9 | -2.8 | -0.7 | -56 | -73 | -78 | – | – | – | – | |
| – | -505.3% | -465.7% | -27.3% | – | – | – | -11,737.4% | -12,485.9% | -1,317.5% | -350.0% | 66.2% | 67.7% | 95.6% | 94.1% | 90.5% | 88.6% | 86.8% | 87.9% | 84.4% | 89.9% | 87.1% | 84.0% | 75.7% | 61.2% | 57.7% | -12.1% | 96.2% | 90.9% | 90.1% | 91.6% | 95.4% | 96.7% | 93.7% | |
| – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | – | 0.0 | 0.0 | 0.0 | – | – | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | -4.81 | -4.20 | -3.33 | -1.92 | -1.51 | -2.06 | -2.95 | -3.51 | -2.61 | -3.52 | -4.00 | -4.45 | -4.48 | -4.27 | -3.88 | -3.62 | -3.56 | -3.08 | -3.03 | -2.44 | -2.20 | -1.69 | -0.41 | -0.46 | -0.53 | -0.51 | -0.30 | -0.35 | |
| – | – | – | – | – | – | 1.63 | 0.82 | 0.59 | 0.63 | 0.56 | 0.51 | 1.09 | 1.46 | 0.78 | 0.74 | 0.41 | 0.09 | 0.01 | 0.04 | 0.04 | 0.06 | 0.07 | 0.04 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -1.04 | -0.84 | -1.08 | -0.45 | -0.57 | – | – | -3.29 | -3.45 | -3.54 | -3.75 | 7.08 | 4.80 | 23.06 | 10.30 | 9.14 | 8.10 | 6.98 | 5.98 | 5.00 | 5.52 | 3.72 | 2.81 | 1.77 | 1.07 | 0.68 | -0.06 | 5.82 | 0.96 | 0.89 | 0.81 | 1.84 | 0.97 | 0.88 | |
| – | – | – | – | – | – | – | -0.25 | -0.22 | -0.20 | -0.13 | -0.82 | -2.87 | -4.44 | -2.66 | -3.40 | -3.40 | -3.42 | -4.31 | -4.14 | -4.24 | -3.75 | -3.37 | -2.93 | -2.52 | -2.19 | -1.94 | -1.17 | -0.22 | -0.22 | -0.28 | -0.30 | -0.21 | -0.25 | |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.